Pnd33 - Payer and Societal Benefit of Peginterferon Beta-1a Versus Glatiramer Acetate in Patients With Relapsing-Remitting Multiple Sclerosis in Italy
Value in Health- United Kingdom
doi 10.1016/j.jval.2018.09.2000
Full Text
Abstract
Available in
Date
October 1, 2018
Authors
Publisher
Elsevier BV